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The non-essential amino acid L-glutamine (Gln) displays potent anti-inﬂammatory activity by deacti-
vating p38 mitogen activating protein kinase and cytosolic phospholipase A2 via induction of MAPK
phosphatase-1 (MKP-1) in an extracellular signal-regulated kinase (ERK)-dependent way. In this study,
the mechanism of Gln-mediated ERK-dependency in MKP-1 induction was investigated. Gln increased
ERK phosphorylation and activity, and phosphorylations of Ras, c-Raf, and MEK, located in the upstream
pathway of ERK, in response to lipopolysaccharidein vitro and in vivo. Gln-induced dose-dependent
transient increases in intracellular calcium ([Ca2þ]i) in MHS macrophage cells. Ionomycin increased
[Ca2þ]i and activation of Ras - ERK pathway, and MKP-1 induction, in the presence, but not in the
absence, of LPS. The Gln-induced pathways involving Ca2þ- MKP-1 induction were abrogated by a
calcium blocker. Besides Gln, other amino acids including L-phenylalanine and L-cysteine (Cys) also in-
duced Ca2þ response, activation of Ras- ERK, and MKP-1 induction, albeit to a lesser degree. Gln and
Cys were comparable in suppression against 2, 4-dinitroﬂuorobenzene-induced contact dermatitis. Gln-
mediated, but not Cys-mediated, suppression was abolished by MKP-1 small interfering RNA. These data
indicate that Gln induces MKP-1 by activating Ca2þ- ERK pathway, which plays a key role in sup-
pression of inﬂammatory reactions.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The non-essential amino acid L-Glutamine (Gln) is an energy
substrate for most cells [1,2], and is important in multiple ways in
the nitrogen- and carbon-skeleton exchange among different tis-
sues [3]. Several studies have demonstrated that Gln has an anti-
inﬂammatory activity in humans [4] and animals [5,6].
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Chonbuk National University
f Korea.activity of Gln, we have shown that Gln was beneﬁcial against
endotoxin shock as well as bronchial allergic asthma by inhibiting
phosphorylation and activity of cytoplasmic phospholipase A2
(cPLA2) [7,8], which has a high selectivity for liberating arachi-
donic acid that is subsequently metabolized by a panel of down-
stream enzymes for eicosanoid production [9,10]. We have sub-
sequently demonstrated that Gln deactivates p38 and c-Jun
N-terminal kinase(JNK) mitogen-activated protein kinases
(MAPKs) by a rapid induction of MAPK phosphatase 1 (MKP-1)
protein in an extracellular signal-regulated kinase (ERK)-depen-
dent way, which was beneﬁcial against fatal endotoxic shock [11],
steroid-resistant airway neutrophilia in allergic asthma [12] and,
in particular, dermatitis [13,14] in mice.
MKP-1, a member of the MKP family, plays a pivotal role in the
negative control of p38 and JNK [15,16]. Given that p38 has a role
in the production of inﬂammatory molecules [17,18], MKP-1 has
been known to functions as a critical negative regulator of in-
ﬂammation. MKP-1 is a labile protein that is normally degraded
via the ubiquitin/proteasome pathway, and its phosphorylationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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phosphorylates MKP-1 on two carboxyl-terminal serine residues
-serine 359 and serine 364, which stabilizes MKP-1 by preventing
the degradation from ubiquitin/proteasome pathway [19]. We
have also demonstrated that ERK inhibitors blocked Gln-induced
MKP-1 phosphorylation and protein induction [11–13], further
supporting a role for ERK in Gln induction of MKP-1.
In this study, we investigated the precise mechanism of Gln-
mediated MKP-1 induction. We found that Gln upregulates MKP-1
expression by activating initial Ca2þ response, followed by Ras/c-
Raf/MEK/ERK pathway.2. Materials and methods
2.1. Animals
Female BALB/c mice (7–8 weeks old, 16–18 g body weight) were
purchased from the Samtako Bio Korea, and kept in our animal
facility for at least 1 week before use. All animals used in this study
were handled using the protocol approved by the Institutional
Animal Care and Use Committee of the Chonbuk National Uni-
versity Medical School.
2.2. Chemicals and reagents
DNFB, LPS derived from Escherichia coli O127:B8 (L3024), and
all L-amino acids used in this study were obtained from Sigma-
Aldrich (St. Louis, MO, USA). U0126, a speciﬁc inhibitor of MEK1/2,
was obtained from Calbiochem (Madison, WI, USA). U0126 dis-
solved in DMSO (12.5 mg/kg) [11]was injected i.p. 24 h before LPS
treatment. The control group received vehicle. The intracellular
calcium chelator, BAPTA-AM was purchased from Calbiochem
(Madison, WI, USA). Fluo 4/AM were purchased from Molecular
Probes (Eugene, OR, USA). Primary antibodies (rabbit anti-Ras,
anti-phospho-c-Raf (Ser338), anti-phospho-MEK1/2 (Ser217/221),
anti-phospho-ERK1/2, and anti-phospho-MKP-1) were obtained
from Cell Signaling Technology (Danvers, MA, USA). Anti-MKP-1
and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) anti-
bodies were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA), and anti-phospho-MBP (clone P12) was from Millipore
Corporation (Billerica, MA, USA).
2.3. Cell culture
MHS murine alveolar macrophage cells (ATCC CRL-2019), were
maintained in RPMI 1640 supplemented with 10% heat inactivated
FBS (Invitrogen, Carlsbad, CA, USA) and 1% antibiotics (Invitrogen,
Carlsbad, CA, USA) at 37 °C in a 5% CO2 atmosphere.
2.4. Immunoblotting
Mice were sacriﬁced by cervical dislocation. Ear samples were
frozen in liquid nitrogen and were stored in 70 °C until analyzed.
Ear samples were homogenized in the Phosphosafe Extraction
Reagent (Novagen, Madison, WI). Immunoblotting analysis was
performed as described previously[13].
2.5. Immunoprecipitation
Lungs and cells were lysed in non-denaturing lysis buffer
containing 20 mM Tris–HCl, pH 8, 137 mM NaCl, 10% glycerol, and
1% Triton X-100, 2 mM EDTA, protease inhibitor cocktail, and
phosphatase inhibitor. Equal amounts of cell or tissue extracts
were incubated with anti-phospho ERK1/2 at a dilution of 1:50 for
4 h at 4 °C in the same total volume of lysis buffer thereafter,protein A/G conjugated agarose beads (Santa Cruz Biotechnology)
was added and incubated overnight. The agarose beads containing
the immunoprecipitate was then washed with the lysis buffer ﬁve
times and ﬁnally collected by centrifugation. After keeping a small
amount of the beads for the kinase assay, the rest of the beads
were suspended in sample buffer and boiled for Western blot
analysis.
2.6. Assay of ERK activity
After challenge, lung samples were weighed (100 mg) and
homogenized in 1 ml of in non-denaturing lysis buffer containing
20 mM Tris–HCl, pH 8, 137 mM NaCl, 10% glycerol, and 1% Triton
X-100, 2 mM EDTA, protease inhibitor cocktail, and phosphatase
inhibitor. Homogenates were then centrifuged at 12,000 g for
20 min at 4 °C to obtain the supernatant. Equal amounts of cell or
tissue extracts were incubated with anti- ERK1/2 at a dilution of
1:50 for 4 h at 4 °C in the same total volume of lysis buffer
thereafter, protein A/G conjugated agarose beads (Santa Cruz
Biotechnology, CA, USA) was added and incubated overnight. The
agarose beads containing the immunoprecipitate was then washed
with the lysis buffer ﬁve times and ﬁnally collected by cen-
trifugation. The washed precipitate was resuspended in 30 ml ki-
nase buffer (15 mM Tris/HCl, pH 7.2, 15 mM MgCl2, and 1 mM di-
thiothreitol). ERK activity assay was analyzed using MAP kinase
assay kits (Merckmilipore, Darmstadt, Germany) according to the
manufacturer's instructions. The assay is based on the ability of
ERK to phosphorylate the speciﬁc substrate, myelin basic protein,
(MBP). The phosphorylated MBP is then analyzed by immunoblot
analysis, probing with a monoclonal Phospho-speciﬁc MBP
antibody.
2.7. Assay of Ras activation
Ras activation was evaluated by measuring an increase in in-
tracellular Ras protein levels as described elsewhere [22,23].
2.8. Measurement of [Ca2þ]I
MHS cells were washed with Hanks’ balanced salt solution
(HBSS; 2 mM CaCl2, 145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 5 mM
D-glucose, 20 mM HEPES, pH 7.3) containing 1% bovine serum
albumin (BSA). MHS cells were incubated with 5 mM Fluo 4/AM
(Molecular Probes) in Hanks’ balanced salt solution for 45 min at
37 °C. The cells were washed three times with HBSS. The MHS cells
were placed on the stage of confocal microscope (Nikon, Tokyo,
Japan) and Fluo 4/AM loaded cells were excited at excitation wa-
velength (F488 nM) and an emission ﬂuorescence was measured
at 530 nm. For the calculation of [Ca2þ]i, the method of by Tsien et
al.[24]was used with the following equation:
[Ca2þ]i¼Kd(F-Fmin)/(Fmax-F), where Kdis 345 nM for Fluo-4, re-
spectively, and F is the observed ﬂuorescence levels. Each tracing
was calibrated for the maximal intensity (Fmax) by the addition of
ionomycin (10 mM) and for the minimal intensity (Fmin) by the
addition of EGTA (50 mM) at the end of each measurement. The
speciﬁc inhibitor for intracellular Ca2þ chelator (BAPTA-AM) was
incubated at a suboptimal concentrations of 50 mM. The inhibitor
was diluted into DMSO. To study Ca2þ entry in cells, Ca2þ free
conditions were used.2.9. Induction of CD
Induction of CD was performed as described previously [13].
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ESR was measured as described previously [13].
2.11. Histological analysis
Histological analysis was performed as described previously
[13].
2.12. Measurement of cytokines and LTB4
Supernatants from ear samples were prepared as described
previously [13]. Levels of IFN-γ, IL-1β and TNF-α were analyzed by
ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions. ELISA kit for LTB4 was from Cayman
Chemical Company (Ann Arbor, MI, USA).
2.13. siRNA interference
siRNA strands for mouse MKP-1 and controls were obtained
from Santa Cruz Biotechnology. In vivo delivery of siRNA was
performed using in vivo-jet polyethyleneimine (PEI, Polyplus-
transfection) (BP 90,018, F-67401 ILLKIRCH CEDEX, France), ac-
cording to the manufacturer's instructions. To conﬁrm that the
MKP-1 siRNA used really blocked the synthesis of its target, anFig. 1. Gln induces MKP-1 induction in an ERK-dependent way. (A) Lungs were remove
given i.p. 5 min after LPS. (B) U0126 (12.5 mg/kg) was injected i.p. 24 h before LPS injectio
(1 mg or 10 mg/mouse). (D) ERK activity against MBP was performed as described in Mate
3–5 mice/time point/experiment is shown.(E). Gln (40 mM) was added to MHS cells (2
80 mM) was added to MHS cells (2106) 5 min after LPS (1 ng/ml) stimulation. Cells
shown.immunoblotting analysis was performed.
2.14. Statistical analyses
All data are shown as mean 7 error of the mean (7SEM).
Statistical comparison was performed using one-way ANOVA fol-
lowed by the Fisher test. Signiﬁcant differences between the
groups were determined using the unpaired Student's t-test. A P-
value o0.05 was considered statistically signiﬁcant.3. Results
3.1. Gln increases ERK phosphorylation and activity
Systemic administration of Gln 5 min after exposure to lipo-
polysaccharide (LPS) resulted in appearance of MKP-1 phosphor-
ylation and protein as early as 5 min in the lungs (Fig. 1(A)). The
effects were abrogated by the MEK inhibitor, U0126 (Fig. 1(B)),
conﬁrming our previous ﬁndings that Gln induction of MKP-1 is
ERK-dependent [11–13]. To investigate the underlying mechanism
of ERK dependency, we assessed the possibility that Gln could
affect ERK activity. Gln was administered i.p. at 5 min post-LPS,
and ERK phosphorylation and activity were observed at 10, 15, and
30 min post-LPS. Gln increased ERK phosphorylation, which wasd at the indicated times after i.v. injection of LPS (50 mg/kg). Gln (750 mg/kg) was
n. Lungs were removed at 20 min (C) Gln (750 mg/kg) was given i.p. 5 min after LPS
rials and Methods. A representative of three to ﬁve independent experiments with
106) 5 min after LPS (1 ng/ml) stimulation. (F) and (G). Gln (20 mM, 40 mM or
were stimulated for 15 min A representative of three independent experiments is
Fig. 2. Gln activates Ras/c-Raf (Ser338)/MEK/ERK pathway in response to LPS. (A) Lungs were removed at the indicated times after i.v. injection of LPS (50 mg/kg). Gln
(750 mg/kg) was given i.p. 5 min after LPS. A representative of ﬁve independent experiments with 3–5 mice/time point/experiment is shown. (B) Gln (40 mM) was added to
MHS cells (2106) 5 min after LPS (1 ng/ml) stimulation (C) and (D) Serum starved MHS cells were pretreated with FTI (10 mM or 20 mM) for 1 h before stimulation with LPS
(1 ng/ml). Gln (40 mM) was added to MHS cells 5 min after LPS. Cells were stimulated for 15 min A representative of three to ﬁve independent experiments is shown.
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(1 mg/mouse) than at a higher concentration (10 mg/mouse) (Fig. 1
(C)). Gln also increased ERK activity with a similar LPS con-
centration kinetics, as was the case for ERK phosphorylation (Fig. 1
(D)). We also examined the effect of Gln in the murine alveolar
macrophage cell line (MHS). LPS-induced MKP-1 phosphorylation
and protein induction at around 30 min, and addition of Gln at
5 min after LPS stimulation resulted in early phosphorylation and
protein induction of MKP-1 as early as within 5 min (Fig. 1(E)).
Additionally, Gln increased not only ERK phosphorylation (Fig. 1
(F)), but also ERK activity (Fig. 1(G)) in dose-dependent manners,
as was evident in vivo.
3.2. Gln activates Ras/c-Raf/MEK/ERK pathway in response to LPS
Regarding the upstream pathway of ERK activation, the Ras/
Raf/MEK/ERK pathway (ERK cascade) is well established [25–28].
Therefore, we assessed whether Gln can activate the pathway. Gln
increased the levels Ras protein, and phosphorylations of c-Raf(Gln failed to phosphorylate b-Raf, data not shown) and MEK
in vivo (Fig. 2(A)) as well as in vitro (Fig. 2(B)). Gln did not exert
such effects in the absence of LPS especially in vivo. The Ras in-
hibitor, farnesyl transferase inhibitor (FTI)-277, inhibited Gln-
mediated increases of Ras, phosphorylation of c-Raf, MEK, and ERK
(Fig. 2(C)), as well as MKP-1 phosphorylation and protein induc-
tion (Fig. 2(D)) in MHS cells. The data indicate that Gln induction
of MKP-1 is mediated via activation of ERK cascade.
3.3. Gln activates ERK cascade by increasing intracellular Ca2þ level
How can Gln modulate the Ras signal? Given that L-amino
acids have been reported to increase intracellular calcium ([Ca2þ]i)
level [29–31]and the positive modulation of Ras signaling path-
ways by an increase in [Ca2þ]i [32–35], we investigated the pos-
sible involvement of Ca2þ in MHS cells. LPS-induced a transient
rise in [Ca2þ]i, and addition of Gln 3 min after LPS-induced an-
other strong Ca2þ increase (Fig. 3(A)). In the absence of LPS, Gln
also induced a transient rise in [Ca2þ]i (Fig. 3(B)). In both cases,
Fig. 3. Gln activates ERK cascade via increasing [Ca2þ]i. (A) MHS cells (2106) were loaded with Fluo 4/AM and then stimulated with the LPS (1 ng/ml) and then with Gln
(40 mM) 3 min later. (B) [Ca2þ]i response in the absence of LPS. (C) Ionomycin (1 mM), 3 min after LPS. (D) Five min after LPS, cells were stimulated with Ionomycin for 15 min
(E) Ionomycin, 5 min after LPS. (F) Cells were pretreated with BAPTA-AM (50 mM) for 30 min before LPS. (G) and (H) Serum starved cells were pretreated with BAPTA-AM for
30 min before LPS and then Gln 5 min later. Cells were cultured for 15 min A representative of three to ﬁve independent experiments is shown. Each point represents mean
7 S. E. of [Ca2þ]i(A–C and F).
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removal of extracellular Ca2þ .
We next examined whether an increase in [Ca2þ]i is re-
sponsible for the Gln-induced activation of the pathways involving
Ras - ERK - MKP-1 using ionomycin. Ionomycin increased the
[Ca2þ]ilevel in the presence of LPS (Fig. 3(c)) and increased
phosphorylation of Ras and ERK (Fig. 3(D)) and induction of MKP-1
(Fig. 3(E)), in the presence, but not in the absence, of LPS. Fur-
thermore, intracellular calcium chelator, BAPTA-AM, abrogated
Gln-induced Ca2þ response (Fig. 3(F)), phosphorylation of Ras,
c-Raf, MEK, and ERK (Fig. 3(G)), and MKP-1 induction (Fig. 3(H)).
Taken together, the data indicate that Gln induction of MKP-1 is
attributed to its ability to induce a rise in [Ca2þ]i, which in turn
activates ERK cascade.3.4. Comparison of other amino acids in their abilities to activateCa2þ/Ras/ERK/MKP-1 pathway
We further investigated the abilities of other amino acids to
activate the pathways, Ca2þ/Ras/ERK/MKP-1. Besides Gln, we in-
cluded the following seven L-amino acids according to their dif-
ferences in R groups: Glycine (Gly) and alanine (Ala) (nonpolar,
aliphatic), phenylalanine (Phe) and tryptophan (Trp) (aromatic),
lysine (Lys) and arginine (Arg) (positively charged), and cysteine
(Cys) (polar, uncharged). Gln has a polar, uncharged R group like
Cys. We excluded the negatively charged group, aspartate and
glutamate because of their poor solubility. In the presence of LPS,
only Gln, Cys, and Phe-induced a transient Ca2þ increase (Fig. 4
(A)) in MHS cells, in the order of their effectiveness: Gln 4 Cys 4
Phe. In the presence of LPS, Gln, Cys, Phe, and Trp were capable of
mobilizing Ca2þ , in the order of their effectiveness: Gln 4 Cys 4
Phe 4 Trp (Fig. 4(B)). Other amino acids were inactive. Taken
together, these data indicated that the polar, uncharged group (Gln
Fig. 4. Effects of L-amino acids on [Ca2þ]i and the Ras/ERK/MKP-1 pathway. (A) and (B) L-amino acids-induced [Ca2þ]i with or without LPS (1 ng/ml). MHS cells (2106)
were loaded with ﬂuorescence probe Fluo 4/AM. (C) and (D) L-amino acids (40 mM) were added MHS cells (2106) 5 min after LPS (1 ng/ml) stimulation. Cells were
cultured for 15 min A representative of three independent experiments is shown. Each point represents mean 7 S. E. of [Ca2þ]i(A and B).
O. Ayush et al. / Biochemistry and Biophysics Reports 7 (2016) 10–19 15and Cys) was effective in inducing Ca2þ mobilization among the
amino acids tested, and aromatic group (Phe and Trp) also induced
Ca2þ response, but these responses were signiﬁcantly smaller
than that evoked by Gln.
We next compared the effects of amino acids on activation of
ERK cascade and MKP-1 induction. Gln, Cys, and Phe, which
showed Ca2þ provoking activities in the presence of LPS, activated
the ERK cascade (Fig. 4(C)) and potentiated MKP-1 inductionand
MKP-1 phosphorylation(Fig. 4(D)).
3.5. Comparison of other amino acids in their activities to suppress
contact dermatitis (CD)
After 2, 4-dinitroﬂuorobenzene (DNFB) challenge, Gln and se-
ven other amino acids (4% in saline) were topically applied on the
ears of mice three times at 5, 10, and 15 min MKP-1 induction in
the ears was assessed. Gln and Cys-induced MKP-1 induction, al-
beit to a lesser degree in the latter case. In contrast to in vitro, Trp
failed to trigger MKP-1 induction (Fig. 5(A)). Application of DNFB
to the ears increased ear swelling response (ESR) by approximately
120% compared with ears of mice that were treated with vehicle.
Among the eight amino acids, only Gln and Cys signiﬁcantly in-
hibited not only DNFB-induced ESR measured at 24 h (Fig. 5(B)),
and marked spongiosis and extensive leukocyte inﬁltration in the
swollen dermis (Fig. 5(C)), but also protein levels of interferon-
gamma (IFN-γ), interleukin (IL)-1β and tumor necrosis factor-al-
pha (TNF-α) in the ears (Fig. 5(D)).
MKP-1 dependency of Gln and Cys suppression of CD was as-
sessed. MKP-1 small interfering RNA (siRNA) signiﬁcantly abro-
gated the Gln inhibition of ear inﬂammation (Fig. 6(A)-(B)) as wellas ear levels of cytokines (Fig. 6(C)). In contrast, MKP-1 siRNA did
not signiﬁcantly affect Cys-mediated inhibition of ear inﬂamma-
tion (Fig. 6(A)-(B)) and ear levels of cytokines (Fig. 6(C)). Given
that one of mechanisms of Gln inhibition of inﬂammation is cPLA2
inhibition [7,8,14], effects of Gln and Cys on cPLA2 phosphorylation
were examined. Gln or Cys application after (DNFB) challenge
resulted in inhibition of cPLA2 phosphorylation (Fig. 7(A)). How-
ever, whereas Gln-induced inhibition was reversed by MKP-1
siRNA, Cys-induced inhibition was not (Fig. 7(B)). Likewise, al-
though Gln and Cys exerted similar inhibitory activities against the
levels of a cPLA2 metabolite, leukotriene B4(LTB4), in the ear tis-
sues, MKP-1 siRNA abrogated the activity of Gln, but not that of
Cys (Fig. 7(C)). Taken together, among the amino acids tested, only
Gln suppressed CD in a MKP-1-dependent manner.4. Discussion
Gln was previously found to show a strong anti-inﬂammatory
activity via ERK-dependent MKP-1 induction. In this study, we
found that this appears to be attributable to its ability to trigger
sequential events – the steps that increase Ca2þ mobilization,
followed by activation of Ras - ERK pathway.
Given that Gln-mediated MKP-1 induction is ERK-dependent
[11,13], we investigated whether Gln can potentiate ERK signaling.
Gln increased ERK phosphorylation and activity. MKP-1 phos-
phorylation and protein induction occurs as early as 5 min after
Gln administration. Similarly, increases of ERK phosphorylation
and activity by Gln were seen within 5 min, suggesting that in-
crease of ERK activity resulted in MKP-1 induction.
Fig. 5. Effects of amino acids with enhancing [Ca2þ]i on suppression of CD. L-amino acids (4% in saline) were topically applied onto the ears three times at 5, 10, and 15 min
(A) Ears were removed at 30 min after DNFB challenge. A representative of ﬁve independent experiments with 3–5 mice/time point/experiment is shown. (B) ESRs were
measured at 0 and 24 h after challenge. (C) H&E staining of the ear sections (scale bar ¼100 mm). (D) Cytokine levels in the ear homogenates. Data in (B) and (D) represent
the mean 7 standard deviation of three independent experiments with ﬁve mice per group. *Po0.05;**Po0.01;***Po0.001.
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growth factors, serum, hormones, and cytokines lead to activation
of ERK MAPK through a signaling cascade [25,36–41]. The signaling
via this cascade is usually initiated by the activation of cell surface
small G proteins, Ras [42], which is localized to the inner leaﬂet of
the plasma membrane and transmit the signal by recruiting Raf
kinases (A-Raf, B-Raf, and C-Raf) to the plasma membrane, where
they can be activated. Activated Raf, in particular C-Raf (formally
Raf-1) binds to and phosphorylates the down-stream dual speciﬁ-
city kinases MEK1 and MEK2, which, in turn, phosphorylate ERK1/2
within a conserved Thr-Glu-Tyr motif in their activation loop
(known as the ERK cascade)[25,26,39,43,44]. Therefore, we ex-
plored whether Gln can activate the upstream kinases of ERK. Gln
increased the levels of Ras protein and phosphorylation of, c-Raf,
and MEK, indicating that Gln activates Ras-ERK pathway. In this
study, we employed anti-phospho-c-Raf (Ser338) to examine Raf
activation. However, given the complexity of Raf regulation by
homo-and hetero-dimerisation as well as phosphorylation [45], we
can not completely rule out the role of other Raf kinase.
What is the possible mechanism by which Gln activates Ras? In
addition to a variety of extracellular stimuli leading to activation ofthe ERK cascade described above, a linkage between Ras activation
and Ca2þhas been described reported in neurons [32–35,46]. One
of mechanisms is that these Ca2þ signals are mediated by
Ca2þ/calmodulin (CaM) protein kinase II (CaMKII), a ubiquitous
serine/threonine protein kinase that is activated by Ca2þ and CaM
to phosphorylate diverse substrates involved in metabolism,
neurotransmitter release and cell cycle control. For example, the
activation of the Ras/Raf/MEK/ERK signal pathway by calcium/
calmodulin is well established [47]. These observations led us to
explore possible cross-talk between these two signal pathways.
Consistent with these ﬁndings, we demonstrated that Gln evoked
Ca2þ mobilization regardless of the presence of LPS in MHS
macrophages. Gln also stimulated signiﬁcant Ca2þ response in the
absence of extracellular Ca2þ , suggesting that it mainly triggers
the release of Ca2þ from an intracellular store. Ionomycin was
comparable to Gln in terms of activation of Ras- ERK and MKP-1
induction in vitro. However, both Gln and ionomycin failed to ac-
tivate the reactions in the absence of LPS, indicating that just Ca2þ
increases are not sufﬁcient to trigger such reactions. Ca2þ blocker
abrogated not only Gln-mediated Ca2þ mobilization as well as the
ERK cascade activation, but also Gln-mediated MKP-1
Fig. 6. MKP-1 siRNA abrogates suppressive activity of Gln against DNFB-induced CD. Mice were i.v. injected with 200 ml of the PEI mixture containing 0.4 nmol siRNA 24 h
before challenge of DNFB. Gln or Cys was applied three times (3) in the ear skin after DNFB challenge. (A) ESRs were measured at 0 and 24 h after challenge. (B) After
measurement of ESR at 24 h, the mice were sacriﬁced, and the ear sections were stained with H&E (scale bar ¼100 mm). (C) Measurement of cytokine levels in the ear tissues
were performed. Data in (A) and (C) represent the mean 7 standard deviation of three independent experiments with ﬁve mice per group. *Po0.05;**Po0.01;***Po0.001.
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amino acids, particularly aromatic amino acids enhance the ste-
reoselective sensitivity of the CaR to its agonists [30]. However,
Gln was the most effective in this study. This may be attributed to
the differences in the concentrations of amino acids (2–3 mM vs.
20–40 mM in this study) or cell type (human embryonic kidney
cell vs. mouse macrophage cell). Taken together, our data indicate
that Gln raises [Ca2þ]i concentration and activates Ras - ERK
pathway, leading to MKP-1 phosphorylation, which prevents the
degradation of MKP-1 protein from ubiquitin/proteasome path-
way, resulting in early and/or sustained induction of MKP-1.
Regarding the effects of other amino acids on triggering the
Ca2þ - MKP-1 pathway, three amino acids – Gln, Cys (polar,
uncharged) and Phe (aromatic) – were capable of mobilizing Ca2þ
and activation of ERK cascade and MKP-1 induction in the pre-
sence of LPS in MHS cells, indicating that Ca2þ mobilizing activity
is closely associated with its activity to trigger Ras-ERK-MKP-1
pathway. Interestingly, only the amino acids with Ca2þ mobilizing
activity (Gln, Cys, and Phe) were able to activate Ras-ERK-MKP-1
pathway, indicating that, besides Gln, other amino acids including
Cys and Phe were capable of MKP-1 induction via Ca-dependent
activation of ERK cascade in vitro.
In contrast to the ﬁndings in vitro, Gln was the only amino acid
to trigger MKP-1 induction signiﬁcantly in a murine model of CD.
Furthermore, only Gln and Cys signiﬁcantly suppressed CD to asimilar extent in terms of ear inﬂammation and ear levels of cy-
tokines. Interestingly, Gln and Cys also similarly inhibited DNFB
challenge-induced cPLA2 phosphorylation and the levels of a cPLA2
metabolite, LTB4, in the ear. When we assessed MKP-1 dependency
of their suppressions using MKP-1 siRNA, MKP-1 siRNA reversed
all the Gln's suppressive activities, conﬁrming our previous ﬁnd-
ings [11–13], whereas Cys's suppressive activities were not sig-
niﬁcantly affected by MKP-1 siRNA. Therefore, our data indicate
that Cys operates other mechanism rather than a mechanism
mediated by MKP-1 in suppression of CD.
Ca2þ-Ras pathway is activated by a great variety of extra-
cellular stimuli, including growth factors, hormones, and cell?
extracellular matrix contacts [48]. Guanine nucleotide binding
protein (G protein)-coupled receptors (GPCRs) form one of the
largest protein families found in nature, thus, representing the
largest family of cell-surface receptors [49,50]. Many GPCRs pos-
sess distinct allosteric sites that can be targeted by exogenous
substances to modulate the receptors’ functions. These allosteric
modulators include a variety of amino acids, ions, lipids, peptides,
and accessory proteins [51]. Therefore, it is possible that, besides
CaR [30,31], Gln binds to allosteric sites on GPCR, resulting in in-
creasing intracellular Ca2þ via activation of the known phospho-
lipase C/ inositol 1,4,5-trisphosphate pathway. The identiﬁcation of
the Gln-binding GPCR requires further study.
Fig. 7. Gln and Cys inhibit cPLA2 phosphorylation, but MKP-1 siRNA abrogates only
Gln-induced inhibition.(A) The ears were removed at the indicated time points
after DNFB challenge. Gln or Cys was applied three times (3) in the ear skin after
DNFB challenge. A representative of three independent experiments with 3–5 mice/
time point/experiment is shown. (B) The ears were removed at 30 min post chal-
lenge. (C) LTB4 level in the ear samples at 24 h after DNFB challenge were calculated
as pg of protein/mg of homogenized tissue solution. Data in (C) represent the mean
7 standard deviation of three independent experiments with ﬁve mice per group.
*Po0.05;**Po0.01;***Po0.001.
O. Ayush et al. / Biochemistry and Biophysics Reports 7 (2016) 10–19185. Conclusions
We have previously demonstrated that Gln deactivates the two
important enzymes involved in inﬂammatory reactions, p38 and
cPLA2, by a rapid induction of MKP-1 protein in an ERK-dependent
way. In this study, we demonstrate that 1) Gln induction of MKP-1
is attributed to its ability to enhance Ca2þ and subsequently acti-
vate the Ras/c-Raf/MEK/ERK pathway, and 2) Gln is the only amino
acid to suppress CD in an exclusively MKP-1-dependent manner.
This study provides important information to improve our
understanding of the mechanisms underlying Gln induction of
MKP-1 and to establish an easier approach to therapeutic strate-
gies for a variety of human inﬂammatory diseases as steroid-re-
placing and/or steroid-sparing agent.Acknowledgements
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